The MIRROR1 pilot study: treatMent of depressIon among older people living in Regional and RemOte aReas

Not Applicable

Terminated

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12616001412426
• Lead Sponsor: WA Medical School - Division Psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-11
• Study Completion: 2018-06-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Aged 65 years or over
- Screens positive on at least one of two questions known as the Whooley depression screening questions: low mood and decreased interest or enjoyment in usual activities.
- Resides in inner (RA2)or outer regional (RA3) or remote (RA4) Western Australia according to the Australian Standard Geographic Classification - Remoteness Areas (ASGC-RA) Classification 2011
-The presence of a Major Depressive Episode according to DSM-V (SCID 1)
- Fluent in written and spoken english

Exclusion Criteria

- Active suicidal plan
- Current or past history of psychosis
- Sensory impairment that interferes with effective communication over the phone or with reading font size 14
- Clinically significant cognitive impairment as evidenced by a score lower than 27 on the Telephone Interview for Cognitive Status(TICSm)(Knopman et al, 2010)
- Plans to move residence during the follow up period
- Does not reside in inner or outer regional or remote Western Australia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Remission of the Major Depressive episode as assessed by administration of Module A (Mood episodes) of the Structured Clinical Interviews for DSM Disorders -1, Research Version. (SCID - 1). <br><br><br>[12 weeks post randomisation<br><br>]

Secondary Outcome Measures

Name	Time	Method
Severity of depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9) <br><br>[12 and 26 weeks post randomisation<br><br><br>];Severity of anxiety symptoms, as measures by the Brief Measure for Assessing Generalized Anxiety Disorder (GAD-7).[12 and 26 weeks];Health-related quality of life, as measured by the 12-item Short-Form health survey; SF-12) [12 and 26 weeks]